Search Results - "Sarangi, V"

Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5‐Fluorouracil Sensitivity in an East African Population by Elraiyah, T, Jerde, CR, Shrestha, S, Wu, R, Nie, Q, Giama, NH, Sarangi, V, Roberts, LR, Offer, SM, Diasio, RB

“…Clinical studies have identified specific genetic variants in dihydropyrimidine dehydrogenase (DPD; DPYD gene) as predictors of severe adverse toxicity to the…”
Get full text

SOMATIC ALTERATIONS IN FOLLICULAR LYMPHOMA ASSOCIATE WITH UNIQUE TUMOR‐CELL TRANCRIPTIONAL STATES AND TUMOR‐IMMUNE MICROENVIRONMENTS by Krull, J., Wenzl, K., Manske, M. K., Hopper, M. A., Larson, M. C., Sarangi, V., Barman, P., Serres, M. R., Khan, S., Novak, A. J., Maurer, M. J., Yang, Z., Rimsza, L., Link, B. K., Habermann, T. M., Ansell, S. M., King, R. L., Cerhan, J. R., Novak, J. P.

Get full text

Genetic diversity of newly diagnosed follicular lymphoma by Asmann, Y W, Maurer, M J, Wang, C, Sarangi, V, Ansell, S M, Feldman, A L, Nowakowski, G S, Manske, M, Price-Troska, T, Yang, Z-Z, Slager, S L, Habermann, T M, Cerhan, J R, Novak, A J

Get full text

An artificial intelligence platform for movement analysis and rehabilitation: Clinical applications of stepsense to complex pain and long covid by Pelah, A., Sarangi, V., de Villiers, E., Shenker, N., Stone, T., Estibeiro, P., Barenholtz, E., Levy, X., Fields, G.

Get full text

Metabolic liver cancer: associations of rare and common germline variants in one-carbon metabolism and DNA methylation genes by Antwi, Samuel O, Heckman, Michael, White, Launia, Yan, Irene, Sarangi, Vivekananda, Lauer, Kimberly P, Reddy, Joseph, Ahmed, Fowsiyo, Veliginti, Swathi, Mejías Febres, Ellis D, Hatia, Rikita I, Chang, Ping, Izquierdo-Sanchez, Laura, Boix, Loreto, Rojas, Angela, Banales, Jesus M, Reig, Maria, Stål, Per, Gómez, Manuel Romero, Singal, Amit G, Li, Donghui, Hassan, Manal M, Roberts, Lewis R, Patel, Tushar

“…Abstract Animal studies implicate one-carbon metabolism and DNA methylation genes in hepatocellular carcinoma (HCC) development in the setting of metabolic…”
Get full text

Inherited variants at 3q13.33 and 3p24.1 are associated with risk of diffuse large B-cell lymphoma and implicate immune pathways by Kleinstern, Geffen, Yan, Huihuang, Hildebrandt, Michelle A T, Vijai, Joseph, Berndt, Sonja I, Ghesquières, Hervé, McKay, James, Wang, Sophia S, Nieters, Alexandra, Ye, Yuanqing, Monnereau, Alain, Brooks-Wilson, Angela R, Lan, Qing, Melbye, Mads, Jackson, Rebecca D, Teras, Lauren R, Purdue, Mark P, Vajdic, Claire M, Vermeulen, Roel C H, Giles, Graham G, Cocco, Pier Luigi, Birmann, Brenda M, Kraft, Peter, Albanes, Demetrius, Zeleniuch-Jacquotte, Anne, Crouch, Simon, Zhang, Yawei, Sarangi, Vivekananda, Asmann, Yan, Offit, Kenneth, Salles, Gilles, Wu, Xifeng, Smedby, Karin E, Skibola, Christine F, Slager, Susan L, Rothman, Nathaniel, Chanock, Stephen J, Cerhan, James R

“…Abstract We previously identified five single nucleotide polymorphisms (SNPs) at four susceptibility loci for diffuse large B-cell lymphoma (DLBCL) in…”
Get full text

P01.02 HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer by Asmann, Y W, Ren, Y, Wickland, D P, Sarangi, V, Tian, S, Carter, J M, Mansfield, A S, Block, MS, Sherman, ME, Knutson, K L, Lin, Y

“…BackgroundTumors acquire numerous mutations during development and progression. These mutations give rise to neoantigens that can be recognized by T cells and…”
Get full text

SOMATIC COPY NUMBER GAINS IN MYC, BCL2, OR BCL6, IN ADDITION TO TRANSLOCATIONS, IDENTIFIES A SUBSET OF AGGRESSIVE ALTERNATIVE-DH/TH DLBCL PATIENTS: PF518 by Krull, J., Wenzl, K., Hartert, K., Manske, M., Sarangi, V., Greipp, P., Maurer, M., Larson, M., Ansell, S., McPhail, E., Habermann, T., King, R., Cerhan, J., Novak, A.

Get full text

PF518 SOMATIC COPY NUMBER GAINS IN MYC, BCL2, OR BCL6, IN ADDITION TO TRANSLOCATIONS, IDENTIFIES A SUBSET OF AGGRESSIVE ALTERNATIVE‐DH/TH DLBCL PATIENTS by Krull, J., Wenzl, K., Hartert, K., Manske, M., Sarangi, V., Greipp, P., Maurer, M., Larson, M., Ansell, S., McPhail, E., Habermann, T., King, R., Cerhan, J., Novak, A.

“…Background: Diffuse Large B Cell Lymphoma (DLBCL) is characterized by both biologic and genetic heterogeneity. While significant therapeutic advances have been…”
Get full text

PF514 LOSS OF 18Q22.1‐Q23 IS SIGNIFICANTLY ASSOCIATED WITH GCB‐DLBCL AND FAILURE TO ACHIEVE EFS24 by Wenzl, K., Manske, M., Hartert, K., Krull, J., Sarangi, V., Greipp, P., Maurer, M., Feldman, A., Ansell, S., Cerhan, J., Novak, A.

“…Background: Recent large next generation sequencing studies have redefined the genomic landscape of diffuse large B‐cell lymphoma (DLBCL). While many of the…”
Get full text

LOSS OF 18Q22.1-Q23 IS SIGNIFICANTLY ASSOCIATED WITH GCB-DLBCL AND FAILURE TO ACHIEVE EFS24: PF514 by Wenzl, K., Manske, M., Hartert, K., Krull, J., Sarangi, V., Greipp, P., Maurer, M., Feldman, A., Ansell, S., Cerhan, J., Novak, A.

Get full text